Pharmaceutical Products: 60%
Health Products: 25%
Chemical Raw Materials: 15%

TOP 3 Markets:
China: 70%
Southeast Asia: 15%
Europe: 10%

Guangdong Zhongsheng Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and chemical raw materials. The main market is China, which is not surprising as the company is based there and benefits from strong demand in the domestic market. Southeast Asia and Europe are also important markets, with Southeast Asia playing a significant role due to its geographical proximity and growing health markets.

Production Sites: Guangdong, China (estimated, as of 2023)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a China-based company that mainly operates in the Guangdong province. The region is known for its strong industrial base and well-developed infrastructure, making it an ideal location for the production of pharmaceutical products.

It is likely that the company will continue to produce in this region, benefiting from the existing logistical and economic advantages. More detailed information on new or additional production sites may be found in the latest company reports or press releases.

Revenue Growth: Estimated 10-12% (2026) Research and Development Investments: Increased by 20% (2025)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. focuses on a growth strategy that heavily emphasizes innovation and expansion into new markets. The company invests significantly in research and development to expand its product range and develop new therapeutic solutions.

Another focus is on internationalization. The company plans to strengthen its presence in emerging markets to benefit from the increasing demand for pharmaceutical products in these regions.

In addition, Zhongsheng pursues a strategy of strategic partnerships and acquisitions to strengthen its market position and integrate new technologies that enhance its competitiveness.

Imported Raw Materials: Chemical raw materials, pharmaceutical active ingredients

Main Supplier Countries: India, Germany, USA

Guangdong Zhongsheng Pharmaceutical Co., Ltd. mainly imports chemical raw materials and pharmaceutical active ingredients that are needed for the production of their products. India is a significant supplier of pharmaceutical active ingredients due to its strong production capacities in this area. Germany and the USA supply high-quality chemical raw materials required for the manufacturing of medicines.

This import strategy enables the company to source high-quality materials at competitive prices, which is crucial for maintaining product quality and margins.

Market Share: Estimated 8% in the Chinese pharmaceutical market (2026)

Research & Development (R&D) Expenses: 12% of revenue (2025)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. has a solid competitive advantage, which is characterized by several factors. The company has secured a significant market share in the Chinese pharmaceutical market, indicating a strong brand presence and a wide product portfolio.

A key aspect of their competitive advantage is the continuous investment in research and development. With 12% of revenue allocated to R&D, the company demonstrates a strong commitment to innovation and the development of new products, helping them stand out from the competition.

Additionally, the company benefits from strategic partnerships and an efficient supply chain, allowing them to reduce costs while ensuring quality. This further strengthens their position in a highly competitive market.

Institutional Investor Share: 28% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Guangdong Zhongsheng Pharmaceutical Co., Ltd. is estimated to be around 28%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company's long-term development.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders do not expect significant changes in their assessment of the company's value or future business prospects. This could be interpreted as a sign of stable corporate governance and a balanced risk-return profile.

Market share of Guangdong Zhongsheng Pharmaceutical Co., Ltd.: 4.2% (2026, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12.5%
3. China Resources Pharmaceutical Group Ltd.: 10.8%
4. CSPC Pharmaceutical Group Ltd.: 9.3%
5. Jiangsu Hengrui Medicine Co., Ltd.: 8.7%
6. Guangdong Zhongsheng Pharmaceutical Co., Ltd.: 4.2%
7. Huadong Medicine Co., Ltd.: 3.9%
8. Tasly Pharmaceutical Group Co., Ltd.: 3.5%
9. Yunnan Baiyao Group Co., Ltd.: 3.2%
10. Tongrentang Technologies Co., Ltd.: 2.8%

Moat of Guangdong Zhongsheng Pharmaceutical Co., Ltd.:

Guangdong Zhongsheng Pharmaceutical Co., Ltd. has a moderate moat, mainly attributed to specialized product lines and strong regional presence. Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a broader product range, Zhongsheng's moat is less pronounced.

The larger competitors have significant advantages in terms of economies of scale, broader geographic coverage, and stronger brands. However, Zhongsheng could strengthen its moat through innovations in niche markets or strategic partnerships. Currently, Zhongsheng's competitive advantage is limited compared to the leading companies.

Revenue Growth: 10% (2025) Research and Development Ratio: 8% of revenue (2025) Market Share in China: 5% (2025)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. achieved a revenue growth of 10% in 2025. This indicates a solid business development, especially in a competitive market like the pharmaceutical industry. The company invests 8% of its revenue in research and development, pointing to strong innovation capabilities and the ambition to develop new products and enhance existing ones.

The 5% market share in China shows that the company holds a significant position in the domestic market. This could suggest stable demand for its products and offers potential for further growth, especially if the company can expand its market presence.

Overall, Guangdong Zhongsheng Pharmaceutical Co., Ltd. appears to be a promising investment due to its growth rates, investments in research and development, and market position. However, potential investors should also consider other factors such as the regulatory environment and competitive landscape before making a final decision.

Dividend Yield: 2.5% (2025)
Dividend History: Continuous payouts since 2018

Guangdong Zhongsheng Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years. The dividend yield was last at 2.5% in 2025. The company has been paying dividends continuously since 2018, indicating a certain reliability in its payouts.

The stability of dividend payments is supported by the company's solid financial performance. However, it is important to monitor the future business development and market conditions to assess the sustainability of the dividend policy.